Pharmaco - Press Releases

Date	Title	Company
09-Dec-2019	HUMMINGBIRD BIOSCIENCE RAISES US$19 MILLION IN SERIES B FINANCING	Hummingbird Bioscience
09-Dec-2019	PHASTAR Gains 2020 ‘Best Companies’ Accreditation for Employee Engagement	PHASTAR
09-Dec-2019	Orgenesis launches Point of Care cell and gene therapy centers within HYGEIA Group’s Greek hospital network	HYGEIA Group
09-Dec-2019	Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients Suffering from Prurigo Nodularis	Galderma
09-Dec-2019	Gelesis Secures Over $84 Million in New Capital to Support Commercialization of PLENITY™	Gelesis
09-Dec-2019	Nouscom – First Patient Dosed in a Phase 1 Trial with NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, in MSI-High Solid Tumors	Nouscom
09-Dec-2019	HVIVO (“HVIVO”) to merge with OPEN ORPHAN PLC (“OPEN ORPHAN”)	The Boards of Open Orphan and hVIVO
09-Dec-2019	Moberg Pharma meets primary endpoint for MOB-015 in a Phase 3 study for the treatment of onychomycosis	Moberg Pharma AB
09-Dec-2019	Eisai Presents New Seizure Freedom and Adherence Data Related to Anti-Epileptic Drug FYCOMPA® at the 2019 American Epilepsy Society Annual Meeting	Eisai Inc.
09-Dec-2019	Eisai Presents New Seizure Freedom and Adherence Data Related to Anti-Epileptic Drug FYCOMPA® at the 2019 American Epilepsy Society Annual Meeting	Eisai Inc.
09-Dec-2019	Eisai Presents New Seizure Freedom and Adherence Data Related to Anti-Epileptic Drug FYCOMPA® at the 2019 American Epilepsy Society Annual Meeting	Eisai Inc.
09-Dec-2019	BJ Bioscience Announces First Patient Dosed in FIH Trial of BJ-001 in Patients with Locally Advanced/Metastatic Solid Tumors	BJ Bioscience Inc.
09-Dec-2019	Hoth Therapeutics And North Carolina State University Initiate Preclinical Gene Therapy Study For The Treatment Of Asthma	Hoth Therapeutics, Inc.
09-Dec-2019	PDL BioPharma Announces Completion of Strategic Review Process	PDL BioPharma, Inc.
09-Dec-2019	Folium Labs Inc Announces Closing of a New Investment Round and Receives NRC-IRAP Grant from the Government of Canada to Support IP Strategy	Folium Labs Inc.
09-Dec-2019	CNS Pharmaceuticals to Participate in the 8th Annual ROTH Deer Valley Corporate Access Event	CNS Pharmaceuticals, Inc.
09-Dec-2019	Efficacy, Durability of Response and Safety of Onvansertib Demonstrated in Completed Phase 1b Trial in AML Patients Presented in Oral Session at ASH	Trovagene, Inc.
09-Dec-2019	AbbVie and Scripps Research announce collaboration to develop a broad range of new therapeutics	AbbVie
09-Dec-2019	CNS Pharmaceuticals to Participate in the 8th Annual ROTH Deer Valley Corporate Access Event	CNS Pharmaceuticals, Inc.
09-Dec-2019	CNS Pharmaceuticals to Participate in the 8th Annual ROTH Deer Valley Corporate Access Event	CNS Pharmaceuticals, Inc.